Clinical studies with the potassium channel activator cromakalim in normotensive and hypertensive subjects.

@article{Donnelly1990ClinicalSW,
  title={Clinical studies with the potassium channel activator cromakalim in normotensive and hypertensive subjects.},
  author={Raymund J Donnelly and Henry L. Elliott and Peter A. Meredith and John L. Reid},
  journal={Journal of cardiovascular pharmacology},
  year={1990},
  volume={16 5},
  pages={790-5}
}
Eight normotensive subjects received single and multiple doses of cromakalim (1 mg) and placebo in a randomised double-blind cross-over study to examine general tolerance to cromakalim and its effects on blood pressure (BP), heart rate (HR), and pressor responses to norepinephrine (NE) and angiotensin II (AII). In a second study, 10 hypertensive patients… CONTINUE READING